Spontaneous

Novartis Rhapsido® receives European Fee approval as first oral focused remedy for power spontaneous urticaria 
Press Releases

Novartis Rhapsido® receives European Fee approval as first oral focused remedy for power spontaneous urticaria 

Dupixent® (dupilumab) Authorized within the U.S. because the First Biologic Drugs for Younger Youngsters with Uncontrolled Persistent Spontaneous Urticaria (CSU)
Partnerships

Dupixent® (dupilumab) Authorized within the U.S. because the First Biologic Drugs for Younger Youngsters with Uncontrolled Persistent Spontaneous Urticaria (CSU)